药品评价
藥品評價
약품평개
Drug Evaluation
2015年
14期
14-18,32
,共6页
非小细胞肺癌%表皮生长因子受体%酪氨酸激酶抑制剂%靶向治疗
非小細胞肺癌%錶皮生長因子受體%酪氨痠激酶抑製劑%靶嚮治療
비소세포폐암%표피생장인자수체%락안산격매억제제%파향치료
Non small cell lung cancer%Epidermal growth factor receptor%Tyrosine kinase inhibitor%Targeted therapy
肺癌是当今世界上对人类健康和生命威胁最大的恶性肿瘤,也是临床治疗疗效最差的恶性肿瘤.非小细胞肺癌(NSCLC)组织中常可检测到表皮生长因子受体(EGFR)的高表达,而EGFR与肿瘤血管生成、肿瘤细胞扩散及增殖有关,其突变可以增强NSCLC对酪氨酸激酶抑制剂(EGFR-TKIs)的敏感性.早期的以吉非替尼为代表的EGFR-TKIs借助于高敏感性用于治疗NSCLC患者效果均较为显著,一度成为治疗非小细胞肺癌的主要治疗药物.但经过长期的使用NSCLC患者对EGFR-TKIs药物产生了耐药性表现,病情出现复发甚至恶化的情况.因此,对于吉非替尼等EGFR-TKIs耐药性进行研究,以期通过靶向耐药性相关分子联合治疗NSCLC具有重要意义.本文对EGFR-TKIs耐药相关的分子靶点及针对该靶点的分子抑制剂治疗NSCLC的最新研究进展进行综述.
肺癌是噹今世界上對人類健康和生命威脅最大的噁性腫瘤,也是臨床治療療效最差的噁性腫瘤.非小細胞肺癌(NSCLC)組織中常可檢測到錶皮生長因子受體(EGFR)的高錶達,而EGFR與腫瘤血管生成、腫瘤細胞擴散及增殖有關,其突變可以增彊NSCLC對酪氨痠激酶抑製劑(EGFR-TKIs)的敏感性.早期的以吉非替尼為代錶的EGFR-TKIs藉助于高敏感性用于治療NSCLC患者效果均較為顯著,一度成為治療非小細胞肺癌的主要治療藥物.但經過長期的使用NSCLC患者對EGFR-TKIs藥物產生瞭耐藥性錶現,病情齣現複髮甚至噁化的情況.因此,對于吉非替尼等EGFR-TKIs耐藥性進行研究,以期通過靶嚮耐藥性相關分子聯閤治療NSCLC具有重要意義.本文對EGFR-TKIs耐藥相關的分子靶點及針對該靶點的分子抑製劑治療NSCLC的最新研究進展進行綜述.
폐암시당금세계상대인류건강화생명위협최대적악성종류,야시림상치료료효최차적악성종류.비소세포폐암(NSCLC)조직중상가검측도표피생장인자수체(EGFR)적고표체,이EGFR여종류혈관생성、종류세포확산급증식유관,기돌변가이증강NSCLC대락안산격매억제제(EGFR-TKIs)적민감성.조기적이길비체니위대표적EGFR-TKIs차조우고민감성용우치료NSCLC환자효과균교위현저,일도성위치료비소세포폐암적주요치료약물.단경과장기적사용NSCLC환자대EGFR-TKIs약물산생료내약성표현,병정출현복발심지악화적정황.인차,대우길비체니등EGFR-TKIs내약성진행연구,이기통과파향내약성상관분자연합치료NSCLC구유중요의의.본문대EGFR-TKIs내약상관적분자파점급침대해파점적분자억제제치료NSCLC적최신연구진전진행종술.
Lung cancer is one of the most malignant tumors in the world, which is the biggest threat to human health and life. The expression of epidermal growth factor receptor was detected in non small cell lung cancer tissues, and EGFR was associated with tumor angiogenesis, tumor cell proliferation and proliferation, and the mutation could enhance the sensitivity of NSCLC to tyrosine kinase inhibitors. Early in the treatment of NSCLC patients with the help of the EGFR-TKIs with the help of Gao Min's sensibility is more remarkable, once became the treatment of non small cell lung cancer. But after a long period of use of EGFR-TKIs patients on the drug resistance of NSCLC, the disease has a relapse or even worse. Therefore, it is important to study the drug resistance of EGFR-TKIs in the combination of targeted drug resistance related molecules in order to study the drug resistance of NSCLC. In this article, we reviewed the latest research progress of EGFR-TKIs drug resistance related molecular targets and the molecular inhibitors of NSCLC.
